All Data
A partner for the pharma and biotech industries to improve patient outcomes & quality of life
Lead Product(s): Clascoterone
Therapeutic Area: Dermatology Product Name: Winlevi
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Cassiopea
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 04, 2020
Details:
Albany Molecular Research has been named as the exclusive supplier of the active pharmaceutical ingredient (API) in Cassiopea SpA’s (SIX: SKIN) recently approved acne treatment, Winlevi® (clascoterone) cream 1%.
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2020
Details:
Pivotal trial showed more than four times as many children achieved itch reduction and more than three times as many children achieved clear or almost clear skin with Dupixent plus topical corticosteroids (TCS) compared to TCS alone.
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Azeloglycine
Therapeutic Area: Dermatology Product Name: Iwostin
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Perrigo Company plc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 02, 2020
Details:
Perrigo has completed the acquisition of three Eastern European OTC skincare and hair loss treatment brands, Emolium®, Iwostin® and Loxon® from Sanofi. The acquisition has opened door for Perrigo's transformation to a consumer-focused, global self-care company.
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Azeloglycine
Therapeutic Area: Dermatology Product Name: Iwostin
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Perrigo Company plc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 11, 2020
Details:
Perrigo will acquire three Eastern European OTC skincare and hair loss treatment brands (Emolium®, Iwostin® and Loxon®) from Sanofi.
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2020
Details:
Recommendation was supported by multiple clinical trials that demonstrated superiority of Dupixent® over placebo in improving disease extent and severity, skin clearance and itch intensity, as well as health-related quality of life.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Risankizumab-rzaa
Therapeutic Area: Dermatology Product Name: Skyrizi
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
Details:
New head-to-head data from the IMMerge Phase 3b open-label study show SKYRIZI demonstrated superiority to COSENTYX at week 52, with 66 percent of SKYRIZI patients achieving completely clear skin (PASI 100) versus 40 percent of COSENTYX patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: SULINNO
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2020
Details:
SULINNO, has been officially approved by the NMPA of China for two new indications, including the treatment of pediatric plaque psoriasis and non-infectious intermediate uveitis, posterior uveitis and panuveitis in adults who do not respond adequately to corticosteroids.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tirbanibulin
Therapeutic Area: Dermatology Product Name: Klisyri
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Athenex
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2020
Details:
Klisyri® (tirbanibulin) is a novel microtubule inhibitor, indicated for the topical treatment of actinic keratosis (AK) on the face or scalp.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: Humira
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2020
Details:
Approval is based on the data from a Japanese phase III clinical trial. The proportion of patients achieving at 100 of the target pyoderma gangrenosum ulcer area reduction at Week 26 of Humira administration was 54.5% in the trail.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
